Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Protease Inhibitors

Saquinavir (Invirase, SQV)

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Excerpt from Table 10a
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Use in Pregnancy
Saquinavir
(SQV)
Invirase

Note:
Must be combined with low-dose RTV for PK boosting.
SQV (Invirase) 
Tablet:
  • 500 mg
Capsule:
  • 200 mg
Standard Adult Dose:
  • SQV 1000 mg plus RTV 100 mg twice a day with food or within 2 hours after a meal

PK in Pregnancy:
  • Based on limited data, SQV exposure may be reduced in pregnancy but this effect is not sufficient to warrant a dose change.

Dosing in Pregnancy:
  • No change in dose indicated.
SQV should not be used during pregnancy.

Contraindicated in patients with pre-existing cardiac conduction system disease. Baseline ECG recommended before starting, because PR and/or QT interval prolongations have been observed.             

Low placental transfer to fetus.b

Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.

Must be boosted with low-dose RTV.
a Individual antiretroviral drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
          High: >0.6
          Moderate: 0.3–0.6
          Low: <0.3

Key to Acronyms: ECG = electrocardiogram; PK = pharmacokinetic; RTV = ritonavir; SQV = saquinavir

Download Guidelines